LENZ Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
152
- Stock Symbol
-
LENZ
- Investments
-
1
- Share Price
-
$3.33
- (As of Thursday Closing)
LENZ Therapeutics General Information
Description
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Contact Information
Website
www.lenz-tx.comCorporate Office
- 201 Lomas Santa Fe Drive
- Suite 300
- Solana Beach, CA 92075
- United States
Corporate Office
- 201 Lomas Santa Fe Drive
- Suite 300
- Solana Beach, CA 92075
- United States
LENZ Therapeutics Timeline
LENZ Therapeutics Stock Performance
As of 19-Nov-2026, LENZ Therapeutics’s stock price is $3.33. Its current market cap is $105M with 31.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.33 | $3.20 | $2.80 - $32.13 | $105M | 31.4M | 885K | -$4.49 |
LENZ Therapeutics Financials Summary
As of 30-Sep-2026, LENZ Therapeutics has a trailing 12-month revenue of $12.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (98,780) | 299,422 | 578,422 | |
| Revenue | 12,359 | 19,088 | 0 | 0 |
| EBITDA | (149,714) | (91,094) | (58,263) | (72,321) |
| Net Income | (140,271) | (82,127) | (49,769) | (69,968) |
| Total Assets | 209,749 | 305,876 | 215,304 | 70,376 |
| Total Debt | 460 | 815 | 1,381 | 329 |
LENZ Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
LENZ Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
LENZ Therapeutics Comparisons
Industry
Financing
Details
LENZ Therapeutics Competitors (8)
One of LENZ Therapeutics’s 8 competitors is Opus Genetics, a Formerly VC-backed company based in Durham, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Opus Genetics | Formerly VC-backed | Durham, NC | ||||
| Kodiak Sciences | Formerly VC-backed | Palo Alto, CA | ||||
| Cloudbreak Pharma | Formerly VC-backed | Irvine, CA | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
LENZ Therapeutics Patents
LENZ Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024249927-A1 | Methods for clinical-scale production of genetically modified primary cells | Inactive | 01-Jun-2023 | ||
| WO-2024137533-A1 | Improved peptide inhibitors of p53 binding protein 53bp1 | Inactive | 19-Dec-2022 | ||
| WO-2024097373-A1 | Methods for genotyping gene-edited hematopoietic stem cells | Inactive | 02-Nov-2022 | ||
| EP-4476344-A2 | Adaptations for high efficiency i-f3-crispr-cas systems for guide rna-directed transposition in human cells | Pending | 09-Feb-2022 | ||
| EP-4476344-A4 | Adaptations for high efficiency i-f3-crispr-cas systems for guide rna-directed transposition in human cells | Pending | 09-Feb-2022 | C07K14/195 |
LENZ Therapeutics Signals
LENZ Therapeutics Acquisitions (1)
LENZ Therapeutics’s most recent deal was a Merger/Acquisition with Graphite Bio. The deal was made on 20-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Graphite Bio | 20-Mar-2024 | Merger/Acquisition | Biotechnology |
LENZ Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.61 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
LENZ Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lenz Therapeutics Operations | Solana Beach, CA | 2017 |
LENZ Therapeutics FAQs
-
When was LENZ Therapeutics founded?
LENZ Therapeutics was founded in 2013.
-
Where is LENZ Therapeutics headquartered?
LENZ Therapeutics is headquartered in Solana Beach, CA.
-
What is the size of LENZ Therapeutics?
LENZ Therapeutics has 152 total employees.
-
What industry is LENZ Therapeutics in?
LENZ Therapeutics’s primary industry is Drug Discovery.
-
Is LENZ Therapeutics a private or public company?
LENZ Therapeutics is a Public company.
-
What is LENZ Therapeutics’s stock symbol?
The ticker symbol for LENZ Therapeutics is LENZ.
-
What is the current stock price of LENZ Therapeutics?
As of 19-Nov-2026 the stock price of LENZ Therapeutics is $3.33.
-
What is the current market cap of LENZ Therapeutics?
The current market capitalization of LENZ Therapeutics is $105M.
-
What is LENZ Therapeutics’s current revenue?
The trailing twelve month revenue for LENZ Therapeutics is $12.4M.
-
Who are LENZ Therapeutics’s competitors?
Opus Genetics, Kodiak Sciences, Cloudbreak Pharma, ONL Therapeutics, and Foventa Therapeutics are some of the 8 competitors of LENZ Therapeutics.
-
What is LENZ Therapeutics’s annual earnings per share (EPS)?
LENZ Therapeutics’s EPS for 12 months was -$4.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process